Gabriele Scimemi
Research Subjects
Gabriele Scimemi has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Dinara Samarkanova
Banc de Sang i Teixits Barcelona Spain
2 shared publications - Larysa Mykhailova
Transfusion Medicine Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy
2 shared publications - Tiziana Montemurro
Transfusion Medicine Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy
2 shared publications - Alessandro Cherubini
Precision Medicine Lab—Biological Resource Center, Transfusion Medicine Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan Italy
1 shared publication - Anthi Gafou
Transfusion Service of GONK Oi Agioi Anargyroi Hospital Athens Greece
1 shared publication Armando Tripodi
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy
1 shared publication
Latest Publications
- Open Access
- 18 January 2026
- Published by Wiley in Transfusion
- Vol. 66 (3) , 543-554
Characterization of allogeneic platelet gel from adult donor blood and umbilical cord blood activated with locally prepared cryoprecipitate and thrombin: A pilot exercise
Background: Characterization of platelet gel (PG) from different blood sources and preparation methods remains incomplete. Study Design and Methods: This study compared the weight, growth factor (GF) content, and gelation dynamics (via rotational thromboelastometry, ROTEM) of allogeneic PG prepared from adult blood (AB) and cord blood (CB) platelet concentrates (PC). ABPC were suspended in 100% plasma or 35% plasma/65% platelet additive solution (PAS), while CBPC were suspended in 100% plasma. PG was prepared in commercial BioNest D mini‐bags using a method with calcium gluconate, locally made cryoprecipitate, and thrombin (CT), or a reference method with calcium gluconate and commercial batroxobin (BA). PG was analyzed at 30 min and 6 h. Results: At 30 min, PG weights were higher with CT than BA across all conditions. With 5 mL ABPC in 100% plasma, weights were 7.20 ± 1.07 g (CT) versus 2.72 ± 0.19 g (BA); with 10 mL ABPC in PAS, 9.49 ± 2.86 g (CT) versus 3.87 ± 3.1 g (BA); and with 4.09 ± 0.45 mL CBPC, 5.62 ± 1.21 g (CT) versus 2.04 ± 0.78 g (BA). All PGs lost mass by 6 h, but CT consistently retained more weight. GF percent retention in the PG at 6 h was higher with CT. ROTEM results showed differences in clotting time and comparable values of maximum clot firmness between PG from AB and CB. Discussion: The CT method is a promising alternative for producing allogeneic PG using affordable, locally sourced reagents.
- 18 January 2026
- Published by Wiley in Transfusion
- Vol. 66 (3) , 543-554
Open AccessCharacterization of allogeneic platelet gel from adult donor blood and umbilical cord blood activated with locally prepared cryoprecipitate and thrombin: A pilot exercise
Background: Characterization of platelet gel (PG) from different blood sources and preparation methods remains incomplete. Study Design and Methods: This study compared the weight, growth factor (GF) content, and gelation dynamics (via rotational thromboelastometry, ROTEM) of allogeneic PG prepared from adult blood (AB) and cord blood (CB) platelet concentrates (PC). ABPC were suspended in 100% plasma or 35% plasma/65% platelet additive solution (PAS), while CBPC were suspended in 100% plasma. PG was prepared in commercial BioNest D mini‐bags using a method with calcium gluconate, locally made cryoprecipitate, and thrombin (CT), or a reference method with calcium gluconate and commercial batroxobin (BA). PG was analyzed at 30 min and 6 h. Results: At 30 min, PG weights were higher with CT than BA across all conditions. With 5 mL ABPC in 100% plasma, weights were 7.20 ± 1.07 g (CT) versus 2.72 ± 0.19 g (BA); with 10 mL ABPC in PAS, 9.49 ± 2.86 g (CT) versus 3.87 ± 3.1 g (BA); and with 4.09 ± 0.45 mL CBPC, 5.62 ± 1.21 g (CT) versus 2.04 ± 0.78 g (BA). All PGs lost mass by 6 h, but CT consistently retained more weight. GF percent retention in the PG at 6 h was higher with CT. ROTEM results showed differences in clotting time and comparable values of maximum clot firmness between PG from AB and CB. Discussion: The CT method is a promising alternative for producing allogeneic PG using affordable, locally sourced reagents.
- Open Access
- 16 February 2025
- Published by Wiley in Vox Sanguinis
- Vol. 120 (5) , 513-516
A procedure using low‐cost reagents to prepare allogeneic platelet gel from standard platelet units
Background and Objectives: Highly effective procedures for the preparation of allogeneic platelet gel (PG) use Ca‐gluconate and batroxobin, an expensive commercial reagent. In this preliminary study, we explored the use of the plasmin‐inhibitor, low‐cost drug tranexamic acid (TXA) in place of batroxobin, based on the literature supporting TXA ability to prevent fibrinolysis and stabilize the gel formed by fibrin polymerization prompted by Ca‐gluconate.Materials and Methods: Eight blood centres determined PG weight and volume of non‐gelled, liquid portion in 116 PG prepared in 20‐mL commercial BioNest D bags. Ten‐millilitre platelet aliquots from platelets in 100% plasma or in 35% plasma/65% platelet additive solution (PAS) were aseptically transferred into the D bag, followed by the injection of 3.3 mL of 10% Ca‐gluconate and 0.4 mL of TXA. After 30‐min incubation, PG weight and non‐gelled liquid volume were determined.Results: PG weight and liquid volume at 30 min were 6.5 ± 3.4 g and 7.4 ± 3.5 mL with platelets in 100% plasma, and 3.7 ± 3.0 g and 10.2 ± 3.3 mL with PAS platelets, respectively.Conclusion: This study provides preliminary evidence supporting the use of TXA as a low‐cost reagent for PG manufacturing from platelets in 100% plasma.
- 16 February 2025
- Published by Wiley in Vox Sanguinis
- Vol. 120 (5) , 513-516
Open AccessA procedure using low‐cost reagents to prepare allogeneic platelet gel from standard platelet units
Background and Objectives: Highly effective procedures for the preparation of allogeneic platelet gel (PG) use Ca‐gluconate and batroxobin, an expensive commercial reagent. In this preliminary study, we explored the use of the plasmin‐inhibitor, low‐cost drug tranexamic acid (TXA) in place of batroxobin, based on the literature supporting TXA ability to prevent fibrinolysis and stabilize the gel formed by fibrin polymerization prompted by Ca‐gluconate.Materials and Methods: Eight blood centres determined PG weight and volume of non‐gelled, liquid portion in 116 PG prepared in 20‐mL commercial BioNest D bags. Ten‐millilitre platelet aliquots from platelets in 100% plasma or in 35% plasma/65% platelet additive solution (PAS) were aseptically transferred into the D bag, followed by the injection of 3.3 mL of 10% Ca‐gluconate and 0.4 mL of TXA. After 30‐min incubation, PG weight and non‐gelled liquid volume were determined.Results: PG weight and liquid volume at 30 min were 6.5 ± 3.4 g and 7.4 ± 3.5 mL with platelets in 100% plasma, and 3.7 ± 3.0 g and 10.2 ± 3.3 mL with PAS platelets, respectively.Conclusion: This study provides preliminary evidence supporting the use of TXA as a low‐cost reagent for PG manufacturing from platelets in 100% plasma.